

EMA/709243/2022

## European Medicines Agency decision P/0403/2022

of 9 September 2022

on the granting of a product specific waiver for pegcetacoplan (Aspaveli), (EMA-002600-PIP04-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Only the English text is authentic.**

# European Medicines Agency decision

P/0403/2022

of 9 September 2022

on the granting of a product specific waiver for pegcetacoplan (Aspaveli), (EMA-002600-PIP04-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Apellis Netherlands B.V. on 21 April 2022 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 22 July 2022 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

**Article 1**

A waiver for pegcetacoplan (Aspaveli), solution for infusion, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 2**

This decision is addressed to Apellis Netherlands B.V., Herikerbergweg 88, 1101 CM - Amsterdam, The Netherlands.

EMA/PDCO/246397/2022  
Amsterdam, 22 July 2022

## Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-002600-PIP04-22

### Scope of the application

**Active substance(s):**

Pegcetacoplan

**Invented name:**

Aspaveli

**Condition(s):**

Treatment of amyotrophic lateral sclerosis

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Solution for infusion

**Route(s) of administration:**

Subcutaneous use

**Name/corporate name of the PIP applicant:**

Apellis Netherlands B.V.

**Information about the authorised medicinal product:**

See Annex II

## Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Apellis Netherlands B.V. submitted to the European Medicines Agency on 21 April 2022 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 23 May 2022.

## Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
  - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

## **Annex I**

### **Grounds for the granting of the waiver**

# 1. Waiver

## **1.1. Condition:**

Treatment of amyotrophic lateral sclerosis

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- solution for infusion, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

## **Annex II**

### **Information about the authorised medicinal product**

**Condition(s) and authorised indication(s):**

1. Treatment of paroxysmal nocturnal haemoglobinuria

Authorised indication(s):

- ASPAVELI is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.

**Authorised pharmaceutical form(s):**

Solution for infusion

**Authorised route(s) of administration:**

Subcutaneous infusion